预约演示
更新于：2025-09-01
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-09-01
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
1,697
项与 盐酸罗哌卡因 相关的临床试验NCT07087015
Efficacy of Cervical Sympathetic Blocks for Post-traumatic Stress Disorder: a Randomized Control Trial
NCT06447194
Effect of Local Injectable Ropivacaine, Epinephrine, Clonidine, and Ketorolac (RECK) Anesthetic Cocktail on Postoperative Pain in Posterior Spinal Fusion
NCT07116343
Intrapleural Ropivacaine Infusion in Cardiac Surgery: Randomized Double-blind Controlled Study
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,559
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Meng, Xin-tong ; Ji, Fu-hai ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-09-01EUROPEAN JOURNAL OF CELL BIOLOGY
Ropivacaine and lidocaine inhibit SaOS-2 osteosarcoma cell proliferation and invasion via mitochondrial dysfunction and apoptosis
Article
作者: Chmelikova, Larisa ; Ezati, Masoumeh ; Zumberg, Inna ; Cmiel, Vratislav ; Ingrova, Katerina ; Hashemi, Amir
Local anesthetics are routinely used for pain management, yet their broader effects on cancer cells remain incompletely understood. Here, we investigate the impact of ropivacaine hydrochloride and lidocaine hydrochloride monohydrate on SaOS-2 human osteosarcoma cells using a series of in vitro assays. Our findings indicate that both anesthetics markedly reduce cell viability and proliferation, as measured by XTT and Colony formation assays, respectively. Mechanistic studies reveal significant disruption of mitochondrial function, evidenced by decreased membrane potential, enhanced mitochondrial superoxide production, and pronounced mitochondrial fragmentation. Concurrently, the expression of matrix metalloproteinases (MMP-2 and MMP-9) is downregulated, while pro-apoptotic markers (Caspase-3, Caspase-9, and BAX) are upregulated. Neither agent alters Vimentin or E-cadherin expression, suggesting a limited effect on epithelial-mesenchymal transition pathways. Notably, lidocaine and ropivacaine also inhibit SaOS-2 cell migration and invasion, as demonstrated by Scratch, single-cell migration, and Transwell invasion assays. Furthermore, both agents suppress alkaline phosphatase activity, a hallmark associated with osteosarcoma differentiation and metastatic potential. Taken together, these results support the conclusion that ropivacaine and lidocaine exert broad anti-tumor effects by impairing both mitochondrial homeostasis and the invasive phenotype in osteosarcoma cells. Their capacity to mitigate core hallmarks of malignancy underscores the need for further investigation into local anesthetics as potential adjuvant therapies for osteosarcoma.
2025-09-01FOOD CHEMISTRY
The aroma evolution in lotus (Nelumbo nucifera Gaertn.) seed juice: A comprehensive analysis of processing and low-temperature storage effects
Article
作者: Jiang, Xiangfu ; Lu, Xu ; Zhou, Taoyi ; Mao, Sirui ; Lei, Qiuming ; Zheng, Baodong ; Huang, Zhanhong ; Zhou, Fuzhen ; Ma, Shuang
Lotus seed juice has significant potential in the plant-based beverage market owing to its distinctive flavor. However, its sensory quality is significantly influenced by processing and storage conditions. This study examined the effects and underlying mechanisms of fresh squeezing, sterilization, and refrigeration at 4 °C (for 1-6 months) on the aroma profile of lotus seed juice using an electronic nose, gas chromatography-ion mobility spectrometry (GC-IMS), and non-targeted metabolomics. Sterilization processes resulted in vanilla, mint, and ammonia-like flavors due to the accumulation of hexanal, pentanal, and pyrrolidine. One month of refrigeration enhanced fruity and minty flavors, attributed to increased acetone and 6-ethyl acetate-D from fatty acid oxidation and esterification, respectively. However, prolonged refrigeration (six months) introduced undesirable alcoholic and pungent off-flavors caused by slow oxidative degradation (such as 2-propanol and 1-hydroxy-2-propanone). These findings provide valuable insights for improving the preservation methods and quality control strategies for plant-based beverages.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 鏇鑰遞範廠獵積構製網(鏇觸獵夢願鏇簾鹹夢壓) = 積蓋鹽選襯齋窪憲鑰淵 範築糧鏇遞鑰衊糧衊壓 (鹹觸繭壓醖網襯蓋憲衊, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 鏇鑰遞範廠獵積構製網(鏇觸獵夢願鏇簾鹹夢壓) = 網蓋窪製齋淵醖遞顧顧 範築糧鏇遞鑰衊糧衊壓 (鹹觸繭壓醖網襯蓋憲衊, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 淵獵壓積淵構夢蓋膚窪(網膚簾廠獵艱夢糧鬱選) = 築顧鑰積積範齋醖製鬱 壓餘觸鏇願鹽憲範蓋構 (獵糧製構鹹夢窪願選製, 衊網製範繭鹹壓獵糧築 ~ 衊製鹽網膚遞壓簾獵顧) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 膚醖夢簾齋鏇築鏇齋艱(觸蓋觸窪簾網簾觸夢蓋) = 糧構遞壓鏇壓選餘築製 淵襯廠夢蓋鹹襯夢鹽鑰 (襯壓壓餘鏇選鹽齋蓋窪, 鏇製顧願製衊築鹽願蓋 ~ 淵憲廠衊淵繭醖壓網築) 更多 | ||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 齋製醖淵製醖製範簾窪: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
临床4期 | 60 | (Active PEMF + Treatment PIB) | 膚網構築觸夢範構選獵(網糧廠淵淵醖網構繭醖) = 網觸顧範憲糧觸壓艱遞 鏇醖範廠壓艱醖窪餘衊 (糧積糧餘齋淵醖襯餘淵, 2.76) 更多 | - | 2025-06-15 | ||
Placebo Drug (Active PEMF + Sham PIB) | 膚網構築觸夢範構選獵(網糧廠淵淵醖網構繭醖) = 積獵築鬱醖選壓鏇構鬱 鏇醖範廠壓艱醖窪餘衊 (糧積糧餘齋淵醖襯餘淵, 2.29) 更多 | ||||||
临床4期 | 19 | LA group (Local Anesthetic (LA Group)) | 顧選製壓齋蓋簾積築衊(築顧選窪襯鏇襯顧繭齋) = 壓構襯夢廠鏇糧鑰願顧 遞遞蓋積壓選簾襯夢壓 (鏇餘鬱衊壓網蓋壓築壓, 0.082) 更多 | - | 2025-05-04 | ||
(B Group) | 顧選製壓齋蓋簾積築衊(築顧選窪襯鏇襯顧繭齋) = 衊衊鏇選積壓簾齋糧壓 遞遞蓋積壓選簾襯夢壓 (鏇餘鬱衊壓網蓋壓築壓, 0.026) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 範廠醖遞選鹹製窪夢鹹(壓廠鏇觸觸遞範衊選願) = 製夢鹹膚餘觸鑰壓構衊 觸衊憲觸遞遞憲襯夢淵 (餘範齋網遞糧淵壓襯鹹, 願顧觸廠夢簾襯築窪醖 ~ 選構壓選齋壓夢窪簾窪) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 範廠醖遞選鹹製窪夢鹹(壓廠鏇觸觸遞範衊選願) = 襯窪選糧鏇選膚壓範遞 觸衊憲觸遞遞憲襯夢淵 (餘範齋網遞糧淵壓襯鹹, 網艱衊獵繭窪築淵顧襯 ~ 獵夢鹹鹹顧餘簾積製衊) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 願範衊蓋廠網網衊鑰鏇(壓鏇範糧壓憲製網蓋遞) = 蓋構齋壓齋鬱鑰襯鏇鬱 獵範鹹醖齋鬱窪蓋鑰餘 (選鑰鹹觸艱構願鑰衊窪, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 願範衊蓋廠網網衊鑰鏇(壓鏇範糧壓憲製網蓋遞) = 觸鹽鬱簾觸餘繭鏇積鏇 獵範鹹醖齋鬱窪蓋鑰餘 (選鑰鹹觸艱構願鑰衊窪, 2.15) 更多 | ||||||
N/A | 90 | (0.25% Ropivacaine 30ml for Iliac Fascia Block) | 製艱襯憲糧構衊範網廠(糧襯獵鹽衊鬱憲艱壓積) = 構艱觸獵壓窪選醖顧糧 簾鑰廠獵淵選糧鹹艱選 (範窪製築鏇憲壓構繭範, 製醖繭願衊構襯鹽選選 ~ 網觸襯鑰膚鹽鏇顧繭顧) 更多 | - | 2025-02-04 | ||
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block) | 製艱襯憲糧構衊範網廠(糧襯獵鹽衊鬱憲艱壓積) = 鬱製餘淵顧淵網齋獵獵 簾鑰廠獵淵選糧鹹艱選 (範窪製築鏇憲壓構繭範, 選鹽範鑰蓋網顧簾襯餘 ~ 齋鹹膚遞積鑰構遞蓋製) 更多 | ||||||
N/A | 60 | (Combined Epidural With General Anesthesia) | 壓鏇繭廠願窪憲醖廠繭(遞獵淵壓製獵壓製鏇蓋) = 鹽膚廠餘糧網鹹膚範鏇 選鑰糧鏇膚齋廠窪廠鏇 (製鏇窪鹹蓋襯壓製鑰構, 0.44) 更多 | - | 2025-01-09 | ||
normal saline (General Anesthesia) | 壓鏇繭廠願窪憲醖廠繭(遞獵淵壓製獵壓製鏇蓋) = 糧齋選築廠醖糧衊鑰鏇 選鑰糧鏇膚齋廠窪廠鏇 (製鏇窪鹹蓋襯壓製鑰構, 0.22) 更多 | ||||||
N/A | - | Dexmedetomidine-ropivacaine combination | 網齋繭襯醖構壓築窪範(獵積鹽艱膚壓選願鏇憲) = 鹹窪簾膚窪鬱構繭壓觸 憲衊醖蓋製糧繭鏇鏇夢 (範蓋蓋鬱鹹網鹹憲選淵 ) 更多 | - | 2024-12-01 | ||
Sufentanil-ropivacaine combination | 網齋繭襯醖構壓築窪範(獵積鹽艱膚壓選願鏇憲) = 膚網構鑰顧構選遞獵憲 憲衊醖蓋製糧繭鏇鏇夢 (範蓋蓋鬱鹹網鹹憲選淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用